


S/N 10/509,292



DT07 Rec'd PCT/PTO 03 JAN 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Drivas, D.)	Examiner:
Serial No.:	10/509,292 ✓)	Group Art Unit:
Filed:	September 23, 2004)	Attorney Docket: MP-01
Title:	Methods and Compositions for Treating and Preventing Eotaxin Mediated Inflammatory Conditions)	

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


In accordance with 37 C.F.R. §§ 1.97 *et. seq.*, Applicant provides the enclosed materials for the Examiner's consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement and the documents listed on the attached Form 1449 and enclosed herewith be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Pursuant to 37 C.F.R. §1.97(b), no fee or statement is required with this Information Disclosure Statement.

The Examiner is invited to contact the Applicant's representative at the below-listed telephone number if there are any questions.

Respectfully submitted,


Date: December 22, 2004


Thomas Hoxie
Reg. No. 32,993


Thomas Hoxie
HOXIE & TSO LLP
374 Millburn Avenue
Suite 300E
Millburn, New Jersey 07041
973-467-2126
973-467-2128 (fax)

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this 22nd day of December, 2004. ^{a box}

Thomas Hoxie
Name


Signature

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/509,292
	Filing Date	September 23, 2004
	First Named Inventor	Dimitrios T. Drivas
	Group Art Unit	
	Examiner Name	
Sheet 1 of 1	Attorney Docket No: MP-01	



US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	2003/0175290A1	9/2003	Renner et al.	
	6,403,782 B1	6/2002	Luster et al.	
	2002/0098523A1	7/2002	Vaughan et al.	
	6,093,405	7/2000	Zagury et al.	
	5,993,814	11/1999	Williams et al.	
	60/396,636		Bachmann et al.	
	60/331,045		Renner et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	WO 03/040164 A2	05-15-2003	Cytos Biotechnology AG		
	WO 02/056905 A2	07-25-2002	Cytos Biotechnology AG		
	WO 01/66754 A1	09-13-2001	Cambridge Antibody Technology Limited		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JOSE, P.J., et al. <i>Eotaxin: Cloning of an Eosinophil Chemoattractant Cytokine and Increased mRNA Expression in Allergen-Challenged Guinea-Pig Lungs</i> , Biochemical and Biophysical Research Communications , November 1994, pages 788-794, Vol. 205, No. 1.	
		JOSE, P.J., et al. <i>Eotaxin: A Potent Eosinophil Chemoattractant Cytokine Detected in a Guinea Pig Model of Allergic Airways Inflammation</i> , J. Exp. Med. , March 1994, pages 881-887, Vol. 179	
		GARCIA-ZEPEDA, E., et al. <i>Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia</i> , Nature Medicine , April 1996, pages 449-456, Vol. 2, No. 4.	

EXAMINER

DATE CONSIDERED